K
Overview
Ketryx offers a Software-as-a-Service Connected Lifecycle Management platform for regulated medical software development. It works by integrating tools for traceability, documentation, Jira, and SBOM management to support planning, development, verification, and maintenance under standards like FDA, IEC 62304, ISO 13485, GMP, and CFR 21 Part 11. The platform targets MedTech teams with an all-in-one lifecycle solution and tiered pricing for startups through large enterprises. Its goal is to reduce compliance risk and development costs while helping customers bring safe, compliant medical software to market faster.
Work here?Claim your company
Simplify's take
What believers are saying
- Ketryx raised $39 million on September 4, 2025, led by Transformation Capital.
- Ketryx announced MCP beta on March 31, 2026, embedding compliance into AI workflows.
- Four of five top Fortune 500 MedTech companies now run on Ketryx.
What critics are saying
- FDA warning letters on AI usage in 2026 punish weak human oversight and validation.
- Siemens Healthineers, Veeva, and Jama can bundle compliance into existing enterprise contracts.
- If Ketryx loses trust in auditability, regulated buyers stop deployments immediately.
What makes Ketryx unique
- Ketryx launched validated AI agents on May 1, 2025, for regulated medical workflows.
- Ketryx holds ISO 13485, IEC 62304, ISO 27001, and SOC 2 Type II.
- Ketryx serves Meta Reality Labs, Flo Health, DeepHealth, HeartFlow, and Fortune 500 MedTech.
Help us improve and share your feedback! Did you find this helpful?
Funding
Notable Investors:
Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Industry standards
Ind Avg. $35M
$4M
$30M
$39M
$45M
$65M
$100M